This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ALBO Panoramica delle azioni
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Albireo Pharma, Inc. Concorrenti
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$44.15 |
| Massimo di 52 settimane | US$45.23 |
| Minimo di 52 settimane | US$16.02 |
| Beta | 1.04 |
| 1Variazione di 1 mese | -1.23% |
| Variazione a 3 mesi | 85.66% |
| Variazione di 1 anno | 66.73% |
| 3Variazione a 3 anni | 98.69% |
| Variazione a 5 anni | 28.53% |
| Variazione dall'IPO | 202.40% |
Notizie e aggiornamenti recenti
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Rendimenti per gli azionisti
| ALBO | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 1.2% | 0.6% | 0.3% |
| 1Y | 66.7% | 27.8% | 38.3% |
Ritorno vs Industria: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
Rendimento vs Mercato: ALBO exceeded the US Market which returned -9.2% over the past year.
Volatilità dei prezzi
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Prezzo delle azioni stabile: ALBO's share price has been volatile over the past 3 months.
Volatilità nel tempo: ALBO's weekly volatility has increased from 17% to 27% over the past year.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc. Riepilogo dei fondamenti
| ALBO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$921.13m |
| Guadagni(TTM) | -US$131.14m |
| Ricavi(TTM) | US$57.39m |
16.1x
Rapporto P/S-7.0x
Rapporto P/EALBO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneGuadagni e ricavi
| ALBO Conto economico (TTM) | |
|---|---|
| Ricavi | US$57.39m |
| Costo del fatturato | US$2.55m |
| Profitto lordo | US$54.84m |
| Altre spese | US$185.99m |
| Guadagni | -US$131.14m |
Ultimi guadagni dichiarati
Sep 30, 2022
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -6.29 |
| Margine lordo | 95.56% |
| Margine di profitto netto | -228.51% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato ALBO nel lungo periodo?
Vedi performance storica e confronto